ENDO canceled due to COVID-19, FDA changes draft guidance for diabetes drugs — top stories in endocrinology
The Endocrine Society annual meeting has been canceled due to COVID-19 concerns. It was the top story last week in endocrinology.
Another top story was about new FDA draft guidance that no longer recommends drug companies conduct cardiovascular outcome trials for type 2 diabetes drugs.
Read these and more of last week’s top stories in endocrinology below:
ENDO canceled due to COVID-19 concerns
The Endocrine Society Board of Directors announced that its annual meeting will be canceled, citing “an unprecedented health emergency” due to the novel coronavirus outbreak. Read more.
FDA draft guidance eliminates CV outcomes trial recommendation for diabetes drug approvals
The FDA issued a new draft guidance that no longer includes a recommendation that drug companies conduct cardiovascular outcomes trials demonstrating safety for all type 2 diabetes drugs, according to an agency press release. Read more.
Pulse-based, TLC diets improve metabolic outcomes in PCOS
Women with polycystic ovary syndrome assigned a diet rich in chickpeas, lentils, dry beans and split peas as part of a lifestyle intervention were just as likely to experience an improvement in metabolic outcomes after 16 weeks as women with PCOS who adhered to the Therapeutic Lifestyle Changes, or TLC, diet, according to findings from a randomized controlled trial published in Clinical Endocrinology. Read more.
Sugar at breakfast may not amplify daily caloric intake
Adults who eat a breakfast high in sugar are no more likely to go on to consume more calories during the day than adults who eat a breakfast lower in sugar, according to findings from a randomized crossover study published in Obesity. Read more.
FDA fast tracks empagliflozin for treatment of chronic kidney disease
The FDA on Thursday granted fast track designation for the investigation of the SGLT2 inhibitor empagliflozin to reduce the risks for renal disease progression and cardiovascular death in adults with chronic kidney disease, according to a press release from Boehringer Ingelheim and Eli Lilly. Read more.